American Association for Cancer Research
00085472can161768-sup-168310_5_supp_3977432_11b551.xlsx (51.64 kB)

Table S3 from Oncogenic RAS Regulates Long Noncoding RNA Orilnc1 in Human Cancer

Download (51.64 kB)
posted on 2023-03-31, 00:44 authored by Dongmei Zhang, Gao Zhang, Xiaowen Hu, Lawrence Wu, Yi Feng, Sidan He, Youyou Zhang, Zhongyi Hu, Lu Yang, Tian Tian, Weiting Xu, Zhi Wei, Yiling Lu, Keith T. Flaherty, Xiaomin Zhong, Gordon B. Mills, Phyllis A. Gimotty, Xiaowei Xu, Meenhard Herlyn, Lin Zhang

Table S3. The lncRNAs and PCGs regulated by Ras in IMR90 cells



Basser Center for BRCA

Dr. Miriam and Sheldon G. Adelson Medical Research Foundation

China Scholarship Council



RAS and its downstream cascades transmit cellular signals, resulting in increased transcription of genes involved in cell growth and division. Protein-coding gene targets of RAS signaling have been characterized extensively, but long noncoding RNAs (lncRNA) regulated by these processes have not. Using a custom-designed lncRNA microarray, we identified the lncRNA Orilnc1 as a genetic target of RAS that is critical for RAS oncogenicity. Orilnc1 expression was regulated by RAS–RAF–MEK–ERK signaling via the transcription factor AP1. Orilnc1 was highly expressed in BRAF-mutant cancers, such as melanoma. Silencing of Orilnc1 blocked tumor cell proliferation and growth in vitro and in vivo. In addition, Orilnc1 blockade reduced expression of cyclin E1 and induced G1–S cell-cycle arrest in tumor cells. Taken together, our results identify Orilnc1 as a novel, nonprotein mediator of RAS/RAF activation that may serve as a therapeutic target in RAS/RAF–driven cancers. Cancer Res; 77(14); 3745–57. ©2017 AACR.

Usage metrics

    Cancer Research